ERBB2 and breast cancer: In breast cancer, Jeong and colleagues found that PMCA2 knockdown disrupted the interaction between HER2 and HSP90 and promoted the internalization and degradation of HER2, resulting in a reduction in the protein levels of p-EGFR, HER3, and p-HER3, but not EGFR (31).